MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more
The Elephant in the Room: Addressing Oncology’s Carbon Footprint
Haleigh BehrmanFrom travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy. Read more
Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History
Haleigh BehrmanLynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community. Read more
Foritinib Gains Momentum in China for ALK-positive NSCLC
Haleigh BehrmanChina’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial. Read more
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
Maaike van den Bos, MD+more
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution. Read more
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
Haleigh BehrmanDuring a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Haleigh BehrmanLacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Dr. Karen Reckamp discusses the challenges that both patients and oncologists in the Los Angeles area experienced during the devastating fires. Read more
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Haleigh BehrmanThough the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent. Read more
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients. Read more
Healthcare Community Can Still Take Action to Combat Effects of Climate Change
Leticia Nogueira, PhD, MPHDr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes. Read more